Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS to present the results of THN102 for Parkinson's Disease at the 2020 International Congress of Parkinson's Disease and Movement Disorders

30/07/2020
Dowload PDF File (643Ko)

THERANEXUS announces its cash position as of 30 June 2020 and implementation of a mandatory convertible bond facility

08/07/2020
Dowload PDF File (489Ko)

THERANEXUS secures €3.4m loan under the French state guarantee scheme (PGE) and provides an update on its developments

24/06/2020
Dowload PDF File (588Ko)

2019 full-year results and update on activities

09/04/2020
Dowload PDF File (351Ko)

Theranexus annouces the success of its phase 2 trial for THN102 in Parkinson's patients

31/03/2020
Dowload PDF File (351Ko)